Morgan Stanley lowered the firm’s price target on Roche to CHF 250 from CHF 260 and keeps an Underweight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RHHBY:
- FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
- Roche enters collaboration agreement with PathAI to develop pathology algorithms
- Repare Therapeutics to regain global rights to Camonsertib
- Roche price target lowered to CHF 215 from CHF 225 at Deutsche Bank
- Roche price target lowered to CHF 250 from CHF 260 at Barclays
